Drew Weissman

On October 2, 2023, Drew Weissman, along with Katalin Karikó, was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in developing the technology that enabled the creation of mRNA vaccines. This was a crowning achievement that recognized his decades of research and its profound impact on modern medicine.

By September 2022, the widespread use and success of mRNA vaccines for COVID-19 had significantly contributed to global pandemic response efforts. The work of Drew Weissman was heavily cited by scientific communities as a pivotal element in achieving quick vaccination milestones, demonstrating the transformative impact of his research in mRNA technology.

Drew Weissman, along with Katalin Karikó, was awarded the Breakthrough Prize in Life Sciences in March 2022. This prize recognized their contributions to the development of mRNA vaccines, which have proven to be a powerful tool in combating the COVID-19 pandemic and represent a new therapeutic class that holds promise for treating a variety of diseases.

In October 2021, Drew Weissman, along with his collaborator Katalin Karikó, was awarded the prestigious Lasker-DeBakey Clinical Medical Research Award. This award recognized their significant contributions to the development of mRNA technology, which was instrumental in the rapid development of vaccines during the COVID-19 pandemic.

On September 14, 2021, Drew Weissman gave a keynote address during the University of Pennsylvania's dedication event for their new research facility. His talk highlighted the potential of mRNA technology beyond vaccines, including its application in therapies for diseases such as cancer and genetic disorders.

The U.S. Food and Drug Administration granted emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine on December 11, 2020. This was a significant milestone as it was the first mRNA vaccine to be authorized for human use, marking a major triumph for mRNA technology based on the foundational work of researchers including Drew Weissman and Katalin Karikó.

By June 2019, awareness and interest in mRNA vaccines were rapidly growing within the scientific community, largely due to the efforts of researchers like Drew Weissman. Numerous studies and conferences began to seriously discuss the implementation and potential applications of mRNA technology beyond infectious diseases.

In December 2005, Drew Weissman and Katalin Karikó published groundbreaking work that demonstrated how modifying nucleosides in mRNA molecules could significantly reduce the immune response to the RNA. This discovery was crucial in making mRNA a viable strategy for vaccines and therapeutics, laying the groundwork for the future development of mRNA vaccines.

Drew Weissman earned his Bachelor of Science (BS) in biochemistry and enzymology from Brandeis University in 1980. His early education laid the groundwork for his future research and contributions to the fields of immunology and vaccine development.

Drew Weissman was born on September 7, 1959, in Lexington, Massachusetts. He would go on to become an influential physician-scientist known for his pioneering research in the field of RNA biology and immunology, which played a crucial role in the development of mRNA vaccines.